Table 2.
Parameters before and after 4 weeks of the trial | Groups | ||||
---|---|---|---|---|---|
I | II | III | IV | V | |
Lycopene in serum, in ng/ml | |||||
before | 110 ± 17 | 110 ± 12 | 210 ± 19 | 90 ± 8.4 | 120 ± 22 |
after | 500 ± 52∗∗ | 310 ± 30∗∗ | 430 ± 30∗∗ | 190 ± 14∗ | 170 ± 27 |
| |||||
Lycopene in cerumen, in ng/g | |||||
before | 53 ± 9.5 | 40 ± 5.5 | 70 ± 10.2 | 750 ± 93 | 14 ± 7.6 |
after | 102 ± 12.4∗ | 100 ± 12.5∗ | 90 ± 11.5 | 2,500 ± 237∗∗ | 12 ± 5.5 |
| |||||
Triglycerides mg/dL | |||||
before | 135±14.9 | 155 ± 12.1 | 128 ± 9.7 | 126 ± 10.2 | 122±13.5 |
after | 133± 11.5 | 150 ± 11.3 | 110 ± 8.5∗ | 123 ± 10.1 | 118 ± 11.7 |
| |||||
LDL, in mg/dL | |||||
before | 144±12.5 | 143 ± 12.4 | 121 ± 10.5 | 137 ± 11.7 | 131±12.1 |
after | 139 ± 10.1∗ | 134 ± 11.2∗ | 104 ± 9.8∗ | 124 ± 10.3∗ | 129 ± 10.2 |
| |||||
HDL, in mg/dL | |||||
before | 41.9±2.9 | 46.5 ± 3.7 | 49.8 ± 3.9 | 50.1 ± 4.2 | 44.0±2.2 |
after | 42.2 ± 3.1 | 47.8 ± 3.9 | 50.0 ± 4.6 | 51.2 ± 4.4 | 45.1 ± 2.4 |
| |||||
IOD, in μM MDA | |||||
before | 142 ± 9.2 | 141 ± 12.7 | 115 ± 10.9 | 164 ± 5.8 | 177 ± 12.1 |
after | 101 ± 8.7∗∗ | 92 ± 8.8∗∗ | 46 ± 4.5∗∗ | 42 ± 3.7∗ | 153 ± 11.9∗ |
| |||||
LDL-Px, in ELISA × 103 | |||||
before | 310 ± 29 | 550 ± 61 | 664 ± 63 | 420 ± 45 | 450 ± 41 |
after | 250 ± 24∗ | 350 ± 29∗∗ | 379 ± 34∗∗ | 130 ± 12∗∗ | 370 ± 32∗ |
| |||||
Lipoprotein O2, in μM | |||||
before | 4.07 ± 0.29 | 3.89 ± 0.35 | 3.86 ± 0.32 | 3.07 ± 0.29 | 3.67 ± 0.31 |
after | 5.26 ± 0.33∗ | 4.64 ± 0.33∗ | 4.55 ± 0.39∗ | 3.44 ± 0.27 | 5.27 ± 0.39∗ |
| |||||
StO2, in AUC mm | |||||
before | 81 ± 6.4 | 66 ± 5.2 | 67 ± 5.1 | 59 ± 4.4 | 76 ± 5.5 |
after | 88 ± 6.9∗ | 79 ± 6.1∗ | 83 ± 7.1∗ | 79 ± 6.3∗ | 76 ± 6.3 |
∗ p < 0.05, ∗∗p < 0.001.